TPST - Tempest Therapeutics Inc. Stock Price, Fair Value and News

3.17USD-0.05 (-1.55%)Market Closed

Market Summary

USD3.17-0.05

Market Closed

-1.55%

TPST Stock Price

View Fullscreen

TPST RSI Chart

TPST Valuation

Market Cap

70.4M

Price/Earnings (Trailing)

-2.37

Price/Sales (Trailing)

1.1K

EV/EBITDA

-1.75

Price/Free Cashflow

-2.65

TPST Price/Sales (Trailing)

TPST Profitability

Operating Margin

-494.44%

EBT Margin

-40618.75%

Return on Equity

-144.24%

Return on Assets

-67.06%

Free Cashflow Yield

-37.67%

TPST Fundamentals

TPST Revenue

Revenue (TTM)

72.0K

TPST Earnings

Earnings (TTM)

-29.8M

Earnings Growth (Yr)

-3.51%

Earnings Growth (Qtr)

-5.56%

Breaking Down TPST Revenue

Last 7 days

-2.5%

Last 30 days

-3.1%

Last 90 days

-16.1%

Trailing 12 Months

53.9%

How does TPST drawdown profile look like?

TPST Financial Health

Current Ratio

3.13

Debt/Equity

0.2

Debt/Cashflow

-6.34

TPST Investor Care

Shares Dilution (1Y)

91.75%

Diluted EPS (TTM)

-1.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	4.0M	2.0M	72.0K	0
2020	0	7.8M	5.9M	0
2018	755.5K	752.5K	5.3M	9.8M
2017	576.0K	471.0K	330.0K	751.5K
2016	567.0K	726.0K	848.0K	659.0K
2015	176.5K	263.0K	349.5K	436.0K
2013	0	0	0	90.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tempest Therapeutics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 29, 2022	woiwode thomas	bought	4,999,990	2.36	2,118,640	-
Jan 07, 2022	dubensky thomas w.	bought	9,560	4.78	2,000	president
Jan 06, 2022	whiting samuel	bought	8,168	4.8048	1,700	chief medical officer
Jun 25, 2021	woiwode thomas	acquired	-	-	997,940	-
Jun 25, 2021	woiwode thomas	acquired	-	-	1,171,090	-
Jun 25, 2021	woiwode thomas	acquired	-	-	7,377	-
Jun 25, 2021	dubensky thomas w.	acquired	-	-	111,343	president
Jun 25, 2021	xu stella	acquired	-	-	579,710	-
Jun 25, 2021	lorenzo pierre	acquired	-	-	53.00	corporate controller
Jun 25, 2021	whiting samuel	acquired	-	-	201	chief medical officer

Which funds bought or sold TPST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	unchanged	-	-51,745	412,895	0.04%
May 16, 2024	JANE STREET GROUP, LLC	new	-	82,251	82,251	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	12.00	12.00	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-440,946	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-156,125	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	643	26,526	31,260	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-12,040	96,077	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-45,320	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	14.86	3,410	168,243	-%
May 15, 2024	MORGAN STANLEY	added	15.64	3,862	143,853	-%

Are Funds Buying or Selling TPST?

Are funds buying TPST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TPST

No. of Funds

Unveiling Tempest Therapeutics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	versant venture capital vi, l.p.	4.5%	997,940	SC 13D/A
Feb 14, 2024	ecor1 capital, llc	0%	0	SC 13G/A
Feb 14, 2024	rock springs capital management lp	0%	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	versant venture capital vi, l.p.	5.2%	997,940	SC 13D/A
Nov 09, 2023	versant venture capital vi, l.p.	7.5%	997,940	SC 13D/A
Feb 14, 2023	rock springs capital management lp	7.83%	823,654	SC 13G/A
Feb 14, 2023	ecor1 capital, llc	9.99%	1,052,810	SC 13G
May 09, 2022	versant venture capital vi, l.p.	9.7%	997,940	SC 13D
Feb 17, 2022	lav regulus ltd	2.2%	153,744	SC 13G

Recent SEC filings of Tempest Therapeutics Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	SC 13D/A	13D - Major Acquisition
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 23, 2024	DEFA14A	DEFA14A
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	ARS	ARS
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Tempest Therapeutics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Tempest Therapeutics Inc. News

Latest updates

Tempest Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q3	2021Q2	2021Q1	2020Q3	2020Q2	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4
Revenue	204.3%	213,000	70,000	66,500	63,000	3,000	3,000	3,000	22,500	42,000	61,500	81,000	67,000	548,500	56,000	84,000	63,000	127,000	197,000	189,000	146,000	316,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	44,000	54,000	112,000	218,000	29,000	274,000	269,000	1,433,000	1,559,000	1,233,000	1,176,000	1,158,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	5,953,000	7,985,000	7,649,000	8,775,000	9,462,000	18,014,000	14,650,000	22,489,000	19,161,000	18,430,000	21,585,000	20,397,000
S&GA Expenses	-10.4%	2,798,000	3,123,000	3,052,000	3,106,000	2,556,000	1,535,000	1,163,000	1,144,000	1,351,000	3,935,000	1,786,000	1,619,000	-	-	-	-	-	-	-	-	-
R&D Expenses	-	-	-	-	-	-	-	-	-	-	1,680,000	2,394,000	2,621,000	3,560,000	4,016,000	4,997,000	5,764,000	4,709,000	4,990,000	5,987,000	5,955,000	4,667,000
EBITDA Margin	0.2%	-377	-378	-381	-387	-14.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-16.2%	389,000	464,000	333,000	437,000	276,000	231,000	-	-	-509,000	228,000	224,000	191,000	-272,500	193,000	186,000	182,000	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	4,000	-	-	-	34,000	11,000	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-5,679,000	-7,703,000	-7,370,000	-8,493,500	-9,356,000	-18,173,000	-14,886,000	-22,659,000	-19,199,000	-18,518,000	-21,683,000	-20,526,000
EBT Margin	0%	-406	-406	-406	-406	-14.51	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	2.4%	-8,947,000	-9,168,000	-8,491,000	-8,110,000	-7,058,000	-5,355,000	-5,431,000	-5,229,000	-10,549,000	-7,536,000	-4,846,000	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-1.5%	-762	-750	-721	-291	-9.07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-7.9%	-9,180,000	-8,509,000	-7,110,000	-11,813,000	57,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-14.0%	44.00	52.00	24.00	31.00	37.00	46.00	63.00	71.00	67.00	73.00	67.00	75.00	73.00	23.00	23.00	57.00	68.00	75.00	58.00	68.00	74.00
Current Assets	-17.0%	33.00	40.00	12.00	19.00	25.00	33.00	60.00	68.00	63.00	69.00	63.00	70.00	69.00	20.00	20.00	54.00	65.00	71.00	54.00	65.00	73.00
Cash Equivalents	-16.4%	33.00	39.00	11.00	18.00	23.00	31.00	43.00	52.00	46.00	52.00	60.00	17.00	52.00	19.00	19.00	28.00	59.00	3.00	48.00	57.00	66.00
Net PPE	9.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-
Liabilities	-4.4%	24.00	25.00	25.00	26.00	26.00	28.00	36.00	36.00	38.00	37.00	24.00	27.00	37.00	5.00	5.00	12.00	13.00	15.00	14.00	13.00	11.00
Current Liabilities	13.6%	11.00	9.00	7.00	9.00	8.00	7.00	24.00	22.00	21.00	20.00	6.00	10.00	20.00	3.00	3.00	10.00	11.00	13.00	11.00	11.00	9.00
Long Term Debt	-33.9%	4.00	6.00	8.00	7.00	9.00	10.00	12.00	13.00	15.00	15.00	15.00	15.00	15.00	-	-	0.00	0.00	0.00	0.00	0.00	0.00
LT Debt, Current	50.7%	6.00	4.00	2.00	3.00	1.00	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
LT Debt, Non Current	-100.0%	-	6.00	8.00	7.00	9.00	10.00	12.00	13.00	15.00	15.00	15.00	15.00	15.00	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Shareholder's Equity	-22.9%	21.00	27.00	-	5.00	11.00	18.00	27.00	35.00	29.00	36.00	44.00	48.00	25.00	33.00	39.00	45.00	55.00	60.00	45.00	55.00	64.00
Retained Earnings	-4.8%	-173	-165	-157	-150	-143	-135	-126	-117	-108	-100	-92.28	-84.17	-100	-71.76	-71.76	-231	-220	-208	-196	-184	-174
Additional Paid-In Capital	0.9%	194	192	157	156	154	154	153	153	138	136	136	132	136	3.00	3.00	275	274	267	239	237	236
Shares Outstanding	0.8%	22.00	22.00	14.00	13.00	11.00	11.00	11.00	12.00	7.00	7.00	7.00	1.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00
Float	-	-	-	-	16.00	-	-	-	22.00	-	-	-	74.00	-	-	-	33.00	-	-	-	124	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-16.4%	-7,186	-6,175	-6,487	-6,392	-8,303	-6,479	-9,072	-8,414	-7,107	-7,985	-11,789	127	-6,310	-4,274	-4,622	40.00	-10,161	-11,691	-8,357	-10,573	-10,601
Share Based Compensation	-100.0%	-	1,097	563	440	446	428	438	367	328	278	296	411	120	-406	91.00	227	1,080	1,188	1,196	994	939
Cashflow From Investing	-2300.0%	-168	-7.00	-	-117	-46.00	-356	-108	-95.00	-3.00	-27.00	14.00	-70.00	-14.00	-5.00	-8.00	33.00	-26.00	-33.00	-87.00	1,132	2,976
Cashflow From Financing	-98.7%	450	34,349	21.00	1,188	44.00	-4,726	350	14,376	1,403	-9.00	3,167	40,961	14,944	30.00	11.00	28,969	5,589	26,860	121	22.00	-60.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TPST Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,340	$ 4,678
General and administrative	3,634	2,903
Loss from operations	(7,974)	(7,581)
Other income (expense), net:
Interest expense	(368)	(344)
Interest income and other income (expense), net	438	289
Total other income (expense), net	70	(55)
Provision for income taxes	0	0
Net loss	$ (7,904)	$ (7,636)
Net loss per share of common stock, RSUs and pre-funded warrants, basic	$ (0.36)	$ (0.55)
Net loss per share of common stock, RSUs and pre-funded warrants, diluted	$ (0.36)	$ (0.55)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic	22,234,225	13,763,173
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	22,234,225	13,763,173

TPST Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,326	$ 39,230
Prepaid expenses and other current assets	1,171	1,133
Total current assets	33,497	40,363
Property and equipment-net	920	840
Operating lease right-of-use assets	9,513	9,952
Other noncurrent assets	448	448
Total assets	44,378	51,603
Current liabilities:
Accounts payable	1,051	845
Accrued expenses	1,524	1,673
Current loan payable (net of discount and issuance costs of $139 and $112, respectively)	6,458	4,285
Current operating lease liabilities	858	952
Accrued compensation	690	1,543
Interest payable	110	113
Total current liabilities	10,691	9,411
Loan payable (net of discount and issuance costs of $454 and $756, respectively)	4,140	6,264
Noncurrent operating lease obligations	8,915	9,160
Total liabilities	23,746	24,835
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 22,217,265 and 22,045,255 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	22	22
Additional paid-in capital	193,777	192,009
Accumulated deficit	(173,167)	(165,263)
Total stockholders’ equity	20,632	26,768
Total liabilities and stockholders’ equity	$ 44,378	$ 51,603

About Tempest Therapeutics Inc.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

CEO	Mr. Stephen R. Brady J.D., LLM
WEBSITE	tempesttx.com
INDUSTRY	Biotechnology
EMPLOYEES	19

Tempest Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for Tempest Therapeutics Inc.? What does TPST stand for in stocks?

TPST is the stock ticker symbol of Tempest Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tempest Therapeutics Inc. (TPST)?

As of Fri May 17 2024, market cap of Tempest Therapeutics Inc. is 70.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TPST stock?

You can check TPST's fair value in chart for subscribers.

What is the fair value of TPST stock?

You can check TPST's fair value in chart for subscribers. The fair value of Tempest Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tempest Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TPST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tempest Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether TPST is over valued or under valued. Whether Tempest Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Tempest Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TPST.

What is Tempest Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TPST's PE ratio (Price to Earnings) is -2.37 and Price to Sales (PS) ratio is 1.06 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TPST PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tempest Therapeutics Inc.'s stock?

In the past 10 years, Tempest Therapeutics Inc. has provided -0.077 (multiply by 100 for percentage) rate of return.